JT
ABUS icon

Jupiter Topco’s Arbutus Biopharma ABUS Stock Holding History

Jupiter Topco’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
+597,423
New +$2.62M ﹤0.01% 1298

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.19B AUM 63.92% 1-Year Est. Return

Jupiter Topco's ABUS Position: Q2 2026 in Review

Jupiter Topco opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 597,423 shares worth $2.87M. The stake represents ﹤0.01% of the portfolio and ranks #1298 among its holdings.

163 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Jupiter Topco held 597,423 shares of Arbutus Biopharma worth $2.87M as of Q2 2026.
  • Arbutus Biopharma was a new Jupiter Topco position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #1298 holding.
  • 163 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.